Governance Frameworks for AI-Driven Genomic Medicine: From Innovation to Responsible Clinical Adoption

Abstract

Artificial intelligence (AI) is advancing genomic medicine through use cases including variant interpretation, disease-risk prediction, precision oncology, rare disease diagnosis, and clinical decision support. While these use cases create a range of opportunities for healthcare, they also pose challenges in the governance of privacy, consent, clinical validation, algorithmic transparency, accountability, equity, and institutional readiness. Because genomic data are highly sensitive and AI systems can be difficult to explain, validate, or reproduce across clinical settings, responsible governance is essential.

This conference paper recommends a governance framework for the ethical collection and clinical application of AI in genomic medicine. The paper utilizes a conceptual framework methodology to establish six predominant governance domains: data, model, clinical, ethical, and organizational governance, including post-deployment governance. The paper posits that AI in genomic medicine should be viewed as a governance continuum, from the collection of data and validation of models, through clinical application, to governance of oversight and periodic reassessment. The framework can assist hospitals, academic medical centers, genomic laboratories, and research institutions, including healthcare regulators, determine if the AI genomic tools are reliable, ethical, clinically pertinent, and institutionally viable.

Keywords: artificial intelligence; genomic medicine; clinical governance; AI ethics; precision medicine; healthcare innovation; institutional readiness.

1. Introduction

Genomic medicine increasingly relies on Artificial intelligence (AI) to analyze large genomic datasets. AI can also support the interpretation of genetic variants and the assessment of risk for disease. AI can also assist in precision oncology, and improve clinical decision-making. These advances are especially critical in genomic medicine and genomics because of the complex biological information that often remains obfuscated and the limitations of existing clinical frameworks for the interpretation of biological information.

Genomic medicine, especially in the field of clinical genomics, has transformed understanding of disease and of risk and opportunities for the prevention and treatment of disease. Genomic medicine facilitates clinical decision-making of a more personalized nature than traditional approaches to genomics and medicine. AI in genomics will help lead to personalized (genomic) medicine for cancer, rare diseases, and prevention (Collins & Varmus, 2015; Ginsburg & Phillips, 2018).

The introduction of AI in precision medicine has also encouraged the transformation of healthcare through the ability of AI to find and interpret actionable clinical insights in large and complex datasets.

The inclusion of AI and digital technologies in genomics and genomic medicine raises important ethical, social, and clinical questions. Genomic data are not simple health data. They may reveal inherited disease risks, biological relationships, ancestry, and long-term health information. AI systems may also operate as technological “black boxes,” making some outputs difficult for clinicians and patients to understand (WHO, 2021; WHO, 2023).

This paper focuses on the lag of institutional governance in the clinical application of AI-based genomic medicine techniques. Disparate interests in the application of AI tools at hospitals and research institutes create bottlenecks in the application of the tools. The evaluation, monitoring and control guidelines are still in the early stages of their creation and development. This creates a gap between technological progress and institutional responsibility.

Advances in AI tools and techniques create new opportunities for AI-based genomic techniques of medicine. This paper does not intend to test AI techniques, instead the paper suggests a control framework for the use of AI tools. Healthcare organizations can use this framework to develop guidelines for the use of genomic AI tools at the pre-implementation, implementation and post-implementation stages of the process.

2. Research Problem and Objectives

While AI in genomic medicine is capable of integrating AI at the hubs of diagnostics and therapeutics due to its genomic basis, many institutions lack the validation, explanation, and oversight infrastructure to employ AI responsibly in genomic medicine. The debates on the relationships between AI and medicine (Kelly, et al., 2019; Yu, et al., 2018) inform us that the clinical impact of an AI system is not determined solely by its algorithms. It also relies strongly on validation, workflows, and professional trust and safety oversight.

The primary research question is:

How can healthcare institutions govern AI-driven genomic medicine in a way that supports innovation while protecting patients, clinicians, and institutional responsibility?

The objectives of this research are to:

1. Analyze the potential obstacles      in the governance of AI in genomic medicine.

2. Discuss the unique challenges      that AI in genomics creates from a governance perspective.

3. Assist the AI genomics      community in the responsible governance of AI in genomics by providing a      governance framework (in a clinical context) composed of six domains.

4. Construct a governance matrix      that institutions can use when assessing AI genomic tools.

Al Souleiman (2026) initiates a discussion on the AI genomic medicine of the future and the importance of institutional governance and regulation.

3. Methodology

This paper is built on the reliance of a conceptual framework. Unlike clinical research, this paper includes no laboratory work, clinical research crowds, or statistical work, instead, this paper strikes a balance between a governance framework and the issues of AI, genomic medicine, healthcare, ethics, and institutional management.

The integration of multiple disciplines is the reason a conceptual framework approach is warranted in this conference paper. Rather than being a purely technological issue, the integration of AI and genomic medicine incorporates multiple facets of clinical, ethical, legal, and organizational issues, as well as challenges of managing communication, safety and preparedness in users, and risks after a product is deployed. This implies that a governance framework should integrate and give practical form to these distinct domains.

The methodology follows three steps.

First, this paper lists the attributes of AI linked to genomic medicine, including the sensitivity of genomic data, the intricacy of the clinical challenge, the significance of societal accountability.

Second, this paper identifies the risks of governance, the management of these risks, and the challenges of privacy, bias, a lack of explainability and validation, and the institution's ability and preparedness.

Third, this paper aims to compile and design a governance framework that provides a risk-based approach to the use of existing AI genomic technologies for healthcare institutions.

This framework is ideal for a conference paper because it provides a starting point for conceptual advancement that is targeted, and can be critiqued and built upon by academics, practitioners, and decision-makers.

4. Key Governance Challenges

4.1 Data Privacy and Consent

Genomic data have the potential to be especially informative, providing insights to a person’s health risk profile and to health risks of their biological relations, which can be particularly vulnerable. AI technologies require increasingly large data sets, which collect, store, and utilize, genomic sequences, clinical data, laboratory data, social data, and possibly more.

Organizations should define how they collect and utilize genomic data from a consent perspective. Participating patients should have a clear understanding of how their data will be utilized and whether the data will be used to train AI algorithms and how that data could be accessible. Consent can no longer be viewed as simply a form that patients sign. Rather, consent should be seen as a developed patient relationship and a communication tool to the signer.

Genetic information can remain sensitive throughout a person’s life and may also affect biological relatives who did not directly provide consent. Therefore, governance systems should include strong data protection measures and clear rules for access, storage, sharing, and secondary use.

4.2 Algorithmic Transparency

Regarding AI model outputs, simplicity and complexity coexist in producing explanations. In genomic medicine, AI outputs may impact a patient’s diagnosis, risk assessment, and/or healthcare management, and therefore this may raise further ethical concerns with explainability and accountability. Many authors have raised such issues with machine learning applications in healthcare (Char et al., 2018).

AI tools are only of use to clinicians and patients if they have a clear and full understanding of the functionality and limitations of such tools. The need to explain the AI model’s outputs to the audience in a non-technical vocabulary remains important, and the boundaries and relevance of such outputs must be clearly defined.

AI systems can assist with the diagnosis of cancer predisposition syndromes by classifying certain genetic variants to be likely pathogenic, and by providing recommendations on the management of genotoxic cancer syndromes. In such circumstances, clinicians must understand whether the AI output is a final recommendation, a probability score, or a decision-support suggestion that requires further review.

4.3 Clinical Validation

There are a number of discrepancies between datasets that are relevant to the clinical setting, and therefore the need to understand the genomic variation across the population is crucial particularly in genomic medicine. AI systems that are trained on poorly or selectively constructed datasets are likely to lead to inequitable healthcare.

There should be a requirement for institutions to present evidence relating to the validation of clinical AI systems. This validation should focus on aspects of technical accuracy, clinical relevance, and the appropriateness of the technology for the local patient context. AI genomic technologies should not be validated as novelty, as they need to be demonstrated as clinically effective and safe.

There is a patient safety element to strong validation. AI systems that provide false information (meaning, false positive and false negative conclusions) may lead to incorrect diagnosis and treatment, inappropriate clinical management, disruption of necessary clinical follow up, and heightened patient concern. AI systems should be validated, and governance of the systems should treat this issue as a core requirement of system design.

4.4 Accountability

Clinical AI should augment the clinical judgment of a practitioner, not replace it. However, the role that AI takes on the clinical judgment of the practitioner is subject to much debate and many interrelated relationships regarding accountability and liability. Practitioners may find that an AI recommendation is incorrect, and they may find it difficult to determine whose responsibility it is for the recommendation.

A governance framework must clarify the role of individuals who assess, and sign off on, the clinical use of AI. Also, the AI governance systems design should treat this issue as a core requirement. The responsibility of clinical AI in high impact clinical output decisions also should remain in the control of a practitioner or a team of practitioners (WHO, 2021; Topol, 2019).

4.5 Bias and Equity

Bias in AI can stem from training on incomplete datasets and equitable bias. In genomics and medicine, this is very important. Genomic databases are comparatively scarce for some populations. If researchers train models mainly on sampled data from some groups, their models would likely perform poorly for other populations.

This is why regulations should include an anti-bias component. Establishments should assess whether AI-based solutions operate reliably for different groups of patients and whether access to AI-based genomic medicine is equitable. Equity should be considered within the scope of clinical quality and should be seen as an integral, structural component.

Bias in genomic AI is likely to impact disease diagnosis, risk evaluation, and treatment recommendations. For this reason, institutions should be concerned not only with the functionality of a model, but also with whom it is likely to work, in what context, and what are the model's potential limitations.

5. Proposed Governance Framework

This study suggests a six-domain framework for governance on the clinical use of AI in genomic medicine. The framework offers accountable governance for clinical use at the institutional level. The six domains are governance of data, models, clinical practice, ethics, organizations, and governance of post-deployment oversight.

5.1 Data Governance

Data governance relates to the constraints of genomic and clinical data. This includes, consent, privacy, data quality, data control, data retention, and data sharing, as well as the legal obligation to be responsible.

Important aspects include:

• legible consent by patients;

• responsible retention of data;

• data retention control;

• legitimate sources of data;

• legitimate constraints on data      use and sharing; and

• protection of the privacy of      relatives.

This governance is a cornerstone of responsible AI in genomic medicine. The absence of safe and responsible data governance makes a highly sophisticated AI system dangerous and indefensible for the apex use of genomic medical data.

5.2 Model Governance

Model governance relates to the AI system. This includes the governance of the development, validation, and documentation of models. It also includes explicability, version management, and monitoring of the models. The NIST AI Risk Management Framework is centered on the governance of AI systems during the AI lifecycle (NIST, 2023).

Important aspects include:

• legitimate channels of use;

• guidelines for validation;

• evidence for model performance;

• legitimate constraints on performance;

• legitimate constraints on and      documentation of model revision;

• evidence for model impact on      the clinical practice.

Model governance is essential for organizations regarding the differentiation of tools for clinical decision support, research, and clinical practice.

5.3 Clinical Governance

Clinical governance concerns the protection of patients when determining updates in clinical workflows. It describes how clinical users should implement the AI outputs in clinical practice.

Some requirements include:

• protocols for clinical AI      outputs;

• specific actions for ambiguous      decisions;

• human analysis of AI outputs;

• multiple-department analysis of      AI outputs;

• training and documentation.

In genomic medicine, running multidisciplinary reviews for decision making and documentation of clinical users’ AI outputs is crucial, as this may include pathway molecular analysis, bioinformatics, clinical decision making, and genomic data, etc.

5.4 Ethical Governance

Ethical governance ensures trust, safety, and fairness with Patient Rights and Dignity. As genomic data is often sensitive and personal, this is of high priority in genomic medicine.

Some requirements include:

• dedicated fairness and      transparency with patients;

• protection for patients of      multiple vulnerabilities;

• communicated and ensured access      to genomic counseling;

• monitoring for AI in high-risk      clinical practice;

• diversity and uncertainty.

Ethical governance must not work only as the final endorsement of AI in genomic medicine, as it must be engrained in its practices.

5.5 Organizational Governance

For AI genomic tools to be safely implemented, several structures must be in place to govern AI tools and govern Genomic AI tools. These structures must include:

• Genomic AI committees of      oversight;

• Clear context of work;

• Procurement oversight;

• Review of Procurement;

• Regulatory review;

• Plan for cybersecurity;

• Internal Persistent Structures.

Many AI implementation failures occur not because the technology is weak, but because the institution is not prepared to manage it responsibly.

5.6 Post-Deployment Monitoring

Governance persists beyond implementation. An AI system’s operation changes over time and can become unpredictable based upon patient population, data, or software changes. The FDA also considers lifecycle changes for AI/ML software for use in medical applications (FDA, 2021).

Key components of governance include:

• continuous performance review;

• incident reporting;

• bias monitoring;

• user feedback;

• patient feedback;

• revalidation after major changes;

• provision to suspend the tool      if it becomes unsafe.

Post-deployment governance assures AI genomic tools remain safe, responsible, and clinically relevant after uptake.

6. Governance Matrix for AI-Driven Genomic Medicine

The following matrix can help to establish a governance structure for the use of AI genomic medicine within a healthcare system. It can also be a useful tool for internal governance and ethics assessments, procurement assessments, and clinical risk assessments.

Governance Domain

Main Question

Evidence Needed

Responsible Unit

Data Governance

Are the   genomic data used legally and ethically?

Consent   records, data protection policy, access controls, data-sharing rules

Data   governance office / ethics committee

Model Governance

Is the AI   model reliable and valid?

Validation studies, performance metrics, model   documentation, intended-use statement

AI review   committee / informatics team

Clinical Governance

Can the   tool be safely used in care?

Clinical   protocol, workflow plan, human review process, escalation procedure

Clinical department / medical board

Ethical Governance

Are   patient rights and fairness protected?

Ethics   approval, bias assessment, patient communication plan, counseling pathway

Ethics committee

Organizational Governance

Is the   institution ready to manage the tool?

Training   plan, accountability map, procurement review, cybersecurity plan

Hospital leadership / governance board

Post-Deployment Monitoring

Will the   tool be reviewed after deployment?

Monitoring   plan, incident reporting process, review schedule, revalidation criteria

Quality   assurance / risk management unit

This matrix does not replace national regulation, professional guidelines, or institutional policy. Rather, it provides a practical structure that can help institutions identify whether major governance requirements have been considered before clinical use.

7. Discussion

The proposed framework illustrated why the adoption of AI-focused genomic medicine needed institutional, as well as technological, readiness. Advanced AI software may be used by a hospital. However, if said hospital does not have trained staff and lacks defined accountability, communication with patients, or monitoring systems, such a tool may not be safe for clinical adoption.

This framework illustrates that governance and risk need proportionality. Not all AI tools are equal, and neither are the levels of control that are needed for them. A governance framework may be simple for a low-risk administrative tool, and for a high-impact genomic tool that will be used for decision-making in cancer care, the governance framework will have to be more comprehensive in the areas of review, validation and monitoring.

It is also critical to the framework that governance of AI genomic medicine be interdisciplinary. Genomic medicine is neither the responsibility of a data science team or a clinical team. It will only be achieved when the numerous disciplines mentioned in the framework (i.e. Clinical, Genetics, Bioinformatics, Data Protections, Ethics, Law, Management, Advocacy, etc.) collaborate.

This framework should help facilitate the numerous conversations that have stemmed from this conference by proposing a customizable framework that health care organizations can use. Future research in institutional readiness, AI regulation, and governance of clinical genomics will likely benefit as well.

The adoption of AI tools, alongside the clarification of responsibilities, mitigation of risks, and provision of reassurance to clinicians/patients, may be facilitated by more comprehensive, enabling governance structures, as opposed to more restrictive, inhibitive governance structures. In this light, the framework illustrates that comprehensive governance structures facilitate clinicians to safely and sustainably adopt Clinical AI.

8. Practical Contribution

The practical contribution of this paper is the establishment of a governance model for healthcare institutions to assist them in addressing the following five questions, before the adoption of AI genomic technologies:

1. Are the data ethically and      legally used?

2. Is the AI model scientifically      valid?

3. Is the tool clinically valuable      and safe?

4. Are patient rights and equity      upheld?

5. Is the institution a proper      steward of the tool?

Answering these questions establishes a contemporary position of healthcare institutions, using AI in genomic medicine, improvement of trust and assignment of risk. In addition to this, the framework should assist in the comparison of AI genomic tools, and the procurement decision making of these tools, ethical review of tools, the training of personnel, and the formulation of institutional policies.

It is particularly beneficial to research institutions, genomic laboratories, and cancer centers, hospitals and academic medical institutions, who are at the early stages of the adoption and implementation of clinically and translationally targeted genomic practices, involving AI.

9. Limitations

This paper is of a conceptual nature, and, by design, does not test the governance framework through empirical research. Accordingly, the governance matrix should be viewed as a conceptual proposal, rather than as an empirical measurement framework. It is hoped that future research will use this framework in the context of hospitals, genomic laboratories, cancer centers, or academic medical institutions, in order to test its practicality.

An additional limitation is the fact that the framework is constructed in the context of a particular set of governance regimes. Hence, organizations are expected to tailor the framework to their own national legal frameworks, data management, and healthcare governance systems.

Furthermore, AI in genomic medicine is developing quickly. New AI methods, new regulations, and new clinical applications may require further refinement of the framework over time.

10. Conclusion

AI-driven genomic medicine has the potential to improve prediction, prevention, and personalized care, but its responsible growth depends on governance. Genomic data are sensitive and AI outputs may alter clinical decisions. If institutions, providers, and policymakers are to ensure the validity of AI medicine, ethics and transparency, along with scrutiny, will be the benchmark.

The focus of this paper is the six-domain governance framework to capture the review of data governance, model governance, clinical governance, ethical governance, organizational governance, and post-deployment governance. Alongside this framework is a governance matrix, a checklist for institutional review.

The main conclusion is that AI-driven genomic medicine should be governed as a lifecycle process. Responsible innovation requires not only advanced technology, but also clear institutional responsibility, patient protection, clinical accountability, and continuous evaluation. By adopting a structured governance approach, healthcare institutions can support innovation while protecting patients, clinicians, and public trust.

References

Al Souleiman, H., Al Souleiman, I. (2026). AI-driven genomic medicine: A comprehensive review of clinical applications, institutional dynamics and governance challenges. Intelligence-Based Medicine.

Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care: Addressing ethical challenges. The New England Journal of Medicine, 378(11), 981–983.

Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. The New England Journal of Medicine, 372(9), 793–795.

Food and Drug Administration. (2021). Artificial Intelligence/Machine Learning-Based Software as a Medical Device Action Plan. U.S. Food and Drug Administration.

Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. Health Affairs, 37(5), 694–701.

Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC Medicine, 17, 195.

National Institute of Standards and Technology NIST. (2023). Artificial Intelligence Risk Management Framework: AI RMF 1.0. U.S. Department of Commerce.

Topol, E. J. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books.

World Health Organization. (2021). Ethics and Governance of Artificial Intelligence for Health. World Health Organization.

World Health Organization. (2023). Regulatory Considerations on Artificial Intelligence for Health. World Health Organization.

Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. Nature Biomedical Engineering, 2, 719–731.